Medicare use of GLP-1 diabetes drugs like Ozempic rose 900% over 5 years, with 2023 spending at $35.8B. HHS report shows ...

AstraZeneca reports positive interim results for camizestrant in Phase 3 SERENA-6 trial, showing PFS benefit in ER-positive ...

Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the company dampened its 2025 sales forecast.

Regeneron is now expecting an accelerated approval decision this summer on its T cell engager for one form of lymphoma, while ...

Eli Lilly is continuing to invest big in US pharma manufacturing, with the addition of three new domestic API sites and ...

FTC court order requires CVS Health to share more documents about Caremark Rx PBM practices as part of ongoing investigation ...

Merck warns Keytruda faces IRA price cuts from 2028, alongside patent expiry and biosimilar competition. Drug hit $29.5B ...

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...

Leo Pharma forecasts first profit since 2018, following restructuring. CEO Bourdon reports strong 2024 sales of 10B DKK, EU ...

Several small clinical trials have demonstrated that gene therapies have restored hearing in children with a rare form of genetic deafness.

Harbour BioMed's subsidiary inks $395M deal, ORIC plans Phase 3 trials, Idorsia updates on deals, Sanofi backs Enveda, Zymeworks gets GSK milestone, BerGenBio ends study, Ignota raises £5.5M ...

To Candel Therapeutics CEO Paul Peter Tak, the biotech’s viral immunotherapy has passed the 'bloody obvious test' in ...